Curasan

Executive Summary

Curasan is a private medical device company headquartered in San Francisco, specializing in biomaterials for bone and tissue regeneration. Founded in 2017, the company develops, manufactures, and distributes synthetic and allograft products under brands such as CERASORB, CERACELL, and OSBONE. Its core technology leverages β-tricalcium phosphate, offering solutions for oral surgeons, periodontists, and orthopedic, trauma, and spine surgeons worldwide. Curasan addresses a growing demand for regenerative materials in dental and orthopedic surgery, competing with both synthetic and biologic alternatives. The company's proprietary formulations aim to enhance bone healing and patient outcomes. While privately held with limited public financial data, its established product portfolio and global distribution indicate a solid market presence. However, the competitive landscape and regulatory hurdles pose ongoing challenges. Curasan's focus on niche applications and incremental innovation positions it for steady growth, but significant scaling may require strategic partnerships or additional funding.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for new CERASORB variant in spine applications70% success
• Q2 2026Strategic distribution agreement with a major dental implant company60% success
• Q4 2026Publication of clinical data supporting OSBONE superiority in orthopedic procedures65% success